Department of Radiation Oncology, Seoul National University College of Medicine, South Korea.
Department of Radiation Oncology, Ewha Womans University College of Medicine, South Korea.
Breast. 2021 Dec;60:272-278. doi: 10.1016/j.breast.2021.11.005. Epub 2021 Nov 15.
To investigate outcomes of salvage whole-brain radiotherapy (WBRT) for recurrent brain metastases (BM) from breast cancer (BC), to identify prognostic factors of overall survival (OS), and to propose a novel prognostic classification for OS in these patients.
We identified 54 patients who had received salvage WBRT as the second brain-focused treatment for recurrent BM from BC (2000-2014). The median follow-up duration was 4.9 months. A recursive partitioning analysis (RPA) was conducted to develop a model to predict OS at the time of salvage WBRT.
The median OS was 6.8 months. OS according to BC-specific graded prognostic assessment (breast-GPA), modified breast-GPA, and updated breast-GPA did not represent our cohort. In the multivariate analysis, a long time before salvage WBRT (≥16 months), control of primary BC or extracranial metastases, systemic treatment after salvage WBRT, and administration of a biologically effective dose for an α/β of 10 Gy (BED10) of salvage WBRT >37.5 Gy showed superior OS. We proposed three RPA classes based on the control of both primary BC and extracranial metastasis and BED10 of salvage WBRT: class I, class II, and class III. In this model, patients with class I experienced the best OS (34.6 months; class II, 5.0 months; class III, 2.4 months; P < 0.001).
In our RPA classification according to the control of both primary BC and extracranial metastasis and the dose of salvage WBRT, significant differences in OS were observed. The subsequent use of a systemic treatment showed better OS.
本研究旨在探讨乳腺癌脑转移(BCBM)患者接受挽救性全脑放疗(WBRT)后的结局,明确总生存(OS)的预后因素,并为该人群的 OS 提出一种新的预后分类。
我们纳入了 54 例接受挽救性 WBRT 治疗复发性 BCBM 的患者(2000-2014 年)。中位随访时间为 4.9 个月。采用递归分区分析(RPA)构建预测挽救性 WBRT 时 OS 的模型。
中位 OS 为 6.8 个月。根据乳腺癌特定分级预后评估(breast-GPA)、改良乳腺癌-GPA 和更新乳腺癌-GPA 评估的 OS 并不能代表本队列。多因素分析显示,挽救性 WBRT 前时间较长(≥16 个月)、BC 和颅外转移得到控制、挽救性 WBRT 后全身治疗、挽救性 WBRT 的生物有效剂量(BED10)>37.5Gy,均与 OS 改善相关。我们基于 BC 和颅外转移的控制情况以及挽救性 WBRT 的 BED10 提出了三种 RPA 分类:Ⅰ类、Ⅱ类和Ⅲ类。在该模型中,Ⅰ类患者的 OS 最佳(34.6 个月;Ⅱ类,5.0 个月;Ⅲ类,2.4 个月;P<0.001)。
根据 BC 和颅外转移的控制情况以及挽救性 WBRT 的剂量,我们的 RPA 分类中观察到 OS 存在显著差异。随后使用全身治疗的患者 OS 更好。